Akebia Therapeutics (AKBA) Share-based Compensation (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Share-based Compensation data on file, last reported at $3.7 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.7 million, up 67.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.8 million (up 67.9% YoY), and the FY2025 annual result was $11.3 million, up 45.12% from the prior year.
• Share-based Compensation grew to $3.7 million in Q1 2026 per AKBA's latest filing, from $3.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.9 million in Q2 2022 and troughed at $1.5 million in Q4 2023.
• A 5-year average of $2.9 million and a median of $2.7 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 50.21% in 2023, then soared 95.69% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2022, then tumbled by 50.21% to $1.5 million in 2023, then increased by 12.09% to $1.7 million in 2024, then jumped by 88.51% to $3.2 million in 2025, then rose by 14.66% to $3.7 million in 2026.
• Business Quant data shows AKBA's Share-based Compensation at $3.7 million in Q1 2026, $3.2 million in Q4 2025, and $3.2 million in Q3 2025.